Rune Andreas Kroken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rune Andreas Kroken has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Erik Johnsen
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
6 shared publications - Hugo A. Jørgensen
Department of Clinical Medicine, Section of Psychiatry, Faculty of Medicine and Dentistry, University of Bergen, Norway
6 shared publications - Else-Marie Løberg
Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway
5 shared publications - Kenneth Hugdahl
Department of Biological and Medical Psychology University of Bergen Bergen Norway
5 shared publications H.A. Jørgensen
Department of Clinical Medicine, Section of Psychiatry, Faculty of Medicine and Dentistry, University of Bergen, Norway
4 shared publicationsE. Johnsen
Division of Psychiatry, Haukeland University Hospital, Pb 23, 5812 Bergen, Norway
3 shared publications
Latest Publications
- Open Access
- 31 January 2019
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 9, 753
Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics
Schizophrenia is considered a syndrome comprised by several disease phenotypes, covering a range of underlying pathologies. One of these disease mechanisms seems to involve immune dysregulation and neuroinflammation. While the current dopamine receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent relapse in the majority of patients with schizophrenia, there is a huge need to explore new treatment options that target other pathophysiological pathways. Such studies should aim at identifying robust biomarkers in order to diagnose and monitor the immune biophenotype in schizophrenia and develop better selection procedures for clinical trials with anti-inflammatory and immune-modulating drugs. In this focused review, we describe available methods to assess inflammatory status and immune disturbances in vivo. We also outline findings of immune disturbances and signs of inflammation at cellular, protein, and brain imaging levels in patients with schizophrenia. Furthermore, we summarize the results from studies with anti-inflammatory or other immune-modulating drugs, highlighting how such studies have dealt with participant selection. Finally, we propose a strategy to construct an immune signature that may be helpful in selecting and monitoring participants in studies with immune modulating drugs and also applicable in regular clinical work.
- 31 January 2019
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 9, 753
Open AccessConstructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics
Schizophrenia is considered a syndrome comprised by several disease phenotypes, covering a range of underlying pathologies. One of these disease mechanisms seems to involve immune dysregulation and neuroinflammation. While the current dopamine receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent relapse in the majority of patients with schizophrenia, there is a huge need to explore new treatment options that target other pathophysiological pathways. Such studies should aim at identifying robust biomarkers in order to diagnose and monitor the immune biophenotype in schizophrenia and develop better selection procedures for clinical trials with anti-inflammatory and immune-modulating drugs. In this focused review, we describe available methods to assess inflammatory status and immune disturbances in vivo. We also outline findings of immune disturbances and signs of inflammation at cellular, protein, and brain imaging levels in patients with schizophrenia. Furthermore, we summarize the results from studies with anti-inflammatory or other immune-modulating drugs, highlighting how such studies have dealt with participant selection. Finally, we propose a strategy to construct an immune signature that may be helpful in selecting and monitoring participants in studies with immune modulating drugs and also applicable in regular clinical work.
- 1 August 2018
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 103, 219-228
Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment
- 1 August 2018
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 103, 219-228
Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment
- Open Access
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
Open AccessThe serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- Open Access
- 11 August 2014
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 4 (6) , 228-239
Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies
Rates of discontinuation of antipsychotic treatment for patients with schizophrenia are high and evidence is limited by selective inclusion and high attrition in randomized controlled trials. To study time to discontinuation of antipsychotic treatment for patients with schizophrenia. All patients with schizophrenia (n = 396) discharged between 2005 and 2011 were followed until discontinuation (clinician or patient decided) of antipsychotic treatment or other endpoints. Univariate and multivariate survival analyses (with time on antipsychotic treatment as the dependent variable) using time-dependent variables were performed. Clozapine displayed lower risk for all-cause (p < 0.001), clinician-decided (p = 0.012) and patient-decided (p = 0.039) discontinuation versus olanzapine oral treatment in the multivariate Cox regression. Second-generation long-acting injection antipsychotics (LAI) (p = 0.015) and first-generation long-acting injection antipsychotics (p = 0.013) showed significantly lower risks for patient-decided discontinuation than olanzapine oral. Higher effectiveness of clozapine and LAI treatment versus oral olanzapine were identified in a clinical cohort of patients with schizophrenia.
- 11 August 2014
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 4 (6) , 228-239
Open AccessTime to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies
Rates of discontinuation of antipsychotic treatment for patients with schizophrenia are high and evidence is limited by selective inclusion and high attrition in randomized controlled trials. To study time to discontinuation of antipsychotic treatment for patients with schizophrenia. All patients with schizophrenia (n = 396) discharged between 2005 and 2011 were followed until discontinuation (clinician or patient decided) of antipsychotic treatment or other endpoints. Univariate and multivariate survival analyses (with time on antipsychotic treatment as the dependent variable) using time-dependent variables were performed. Clozapine displayed lower risk for all-cause (p < 0.001), clinician-decided (p = 0.012) and patient-decided (p = 0.039) discontinuation versus olanzapine oral treatment in the multivariate Cox regression. Second-generation long-acting injection antipsychotics (LAI) (p = 0.015) and first-generation long-acting injection antipsychotics (p = 0.013) showed significantly lower risks for patient-decided discontinuation than olanzapine oral. Higher effectiveness of clozapine and LAI treatment versus oral olanzapine were identified in a clinical cohort of patients with schizophrenia.
- 1 May 2014
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 29 (4) , 246-252
Self-harm induced somatic admission after discharge from psychiatric hospital – a prospective cohort study
Background:Few studies have examined rate and predictors of self-harm in discharged psychiatric patients.Aims:To investigate the rate, coding, timing, predictors and characteristics of self-harm induced somatic admission after discharge from psychiatric acute admission.Method:Cohort study of 2827 unselected patients consecutively admitted to a psychiatric acute ward during three years. Mean observation period was 2.3 years. Combined register linkage and manual data examination. Cox regression was used to investigate covariates for time to somatic admission due to self-harm, with covariates changing during follow-up entered time dependently.Results:During the observation period, 10.5% of the patients had 792 somatic self-harm admissions. Strongest risk factors were psychiatric admission due to non-suicidal self-harm, suicide attempt and suicide ideation. The risk was increased throughout the first year of follow-up, during readmission, with increasing outpatient consultations and in patients diagnosed with recurrent depression, personality disorders, substance use disorders and anxiety/stress-related disorders. Only 49% of the somatic self-harm admissions were given hospital self-harm diagnosis.Conclusions:Self-harm induced somatic admissions were highly prevalent during the first year after discharge from acute psychiatric admission. Underdiagnosing of self-harm in relation to somatic self-harm admissions may cause incorrect follow-up treatments and unreliable register data.
- 1 May 2014
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 29 (4) , 246-252
Self-harm induced somatic admission after discharge from psychiatric hospital – a prospective cohort study
Background:Few studies have examined rate and predictors of self-harm in discharged psychiatric patients.Aims:To investigate the rate, coding, timing, predictors and characteristics of self-harm induced somatic admission after discharge from psychiatric acute admission.Method:Cohort study of 2827 unselected patients consecutively admitted to a psychiatric acute ward during three years. Mean observation period was 2.3 years. Combined register linkage and manual data examination. Cox regression was used to investigate covariates for time to somatic admission due to self-harm, with covariates changing during follow-up entered time dependently.Results:During the observation period, 10.5% of the patients had 792 somatic self-harm admissions. Strongest risk factors were psychiatric admission due to non-suicidal self-harm, suicide attempt and suicide ideation. The risk was increased throughout the first year of follow-up, during readmission, with increasing outpatient consultations and in patients diagnosed with recurrent depression, personality disorders, substance use disorders and anxiety/stress-related disorders. Only 49% of the somatic self-harm admissions were given hospital self-harm diagnosis.Conclusions:Self-harm induced somatic admissions were highly prevalent during the first year after discharge from acute psychiatric admission. Underdiagnosing of self-harm in relation to somatic self-harm admissions may cause incorrect follow-up treatments and unreliable register data.
- Open Access
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 5, 11
A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation
Antipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 receptors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections has been considered mandatory for the antipsychotic action of the drugs. Current drugs effectively target the positive symptoms of psychosis such as hallucinations and delusions in the majority of patients, whereas effect sizes are smaller for negative symptoms and cognitive dysfunctions. With the understanding that neurocognitive dysfunction associated with schizophrenia have a greater impact on functional outcome than the positive symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential effect of future drugs on cognitive enhancement. A major obstacle is, however, that the biological underpinnings of cognitive dysfunction remain largely unknown. With the availability of increasingly sophisticated techniques in molecular biology and brain imaging, this situation is about to change, with major advances being made in identifying the neuronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be revealed. In relation to cognitive effects, this review focuses on evidence from basic neuroscience and clinical studies, taking two separate perspectives. One perspective is the identification of previously under-recognized treatment targets for existing antipsychotic drugs, including myelination and mediators of inflammation. A second perspective is the development of new drugs or novel treatment targets for well-known drugs which act on recently discovered treatment targets for cognitive enhancement, and which may complement the existing drugs. This might pave the way for personalized treatment regimens for patients with schizophrenia aimed at improved functional outcome. The review also aims at identifying major current constraints for pro-cognitive drug development for patients with schizophrenia.
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 5, 11
Open AccessA Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation
Antipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 receptors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections has been considered mandatory for the antipsychotic action of the drugs. Current drugs effectively target the positive symptoms of psychosis such as hallucinations and delusions in the majority of patients, whereas effect sizes are smaller for negative symptoms and cognitive dysfunctions. With the understanding that neurocognitive dysfunction associated with schizophrenia have a greater impact on functional outcome than the positive symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential effect of future drugs on cognitive enhancement. A major obstacle is, however, that the biological underpinnings of cognitive dysfunction remain largely unknown. With the availability of increasingly sophisticated techniques in molecular biology and brain imaging, this situation is about to change, with major advances being made in identifying the neuronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be revealed. In relation to cognitive effects, this review focuses on evidence from basic neuroscience and clinical studies, taking two separate perspectives. One perspective is the identification of previously under-recognized treatment targets for existing antipsychotic drugs, including myelination and mediators of inflammation. A second perspective is the development of new drugs or novel treatment targets for well-known drugs which act on recently discovered treatment targets for cognitive enhancement, and which may complement the existing drugs. This might pave the way for personalized treatment regimens for patients with schizophrenia aimed at improved functional outcome. The review also aims at identifying major current constraints for pro-cognitive drug development for patients with schizophrenia.
- Open Access
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Open AccessHallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Corrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Open AccessCorrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Open AccessCorrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7, 144
The role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations
Auditory verbal hallucinations (AVHs) are a subjective experience of "hearing voices" in the absence of corresponding physical stimulation in the environment. The most remarkable feature of AVHs is their perceptual quality, that is, the experience is subjectively often as vivid as hearing an actual voice, as opposed to mental imagery or auditory memories. This has lead to propositions that dysregulation of the primary auditory cortex (PAC) is a crucial component of the neural mechanism of AVHs. One possible mechanism by which the PAC could give rise to the experience of hallucinations is aberrant patterns of neuronal activity whereby the PAC is overly sensitive to activation arising from internal processing, while being less responsive to external stimulation. In this paper, we review recent research relevant to the role of the PAC in the generation of AVHs. We present new data from a functional magnetic resonance imaging (fMRI) study, examining the responsivity of the left and right PAC to parametrical modulation of the intensity of auditory verbal stimulation, and corresponding attentional top-down control in non-clinical participants with AVHs, and non-clinical participants with no AVHs. Non-clinical hallucinators showed reduced activation to speech sounds but intact attentional modulation in the right PAC. Additionally, we present data from a group of schizophrenia patients with AVHs, who do not show attentional modulation of left or right PAC. The context-appropriate modulation of the PAC may be a protective factor in non-clinical hallucinations.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7, 144
Open AccessThe role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations
Auditory verbal hallucinations (AVHs) are a subjective experience of "hearing voices" in the absence of corresponding physical stimulation in the environment. The most remarkable feature of AVHs is their perceptual quality, that is, the experience is subjectively often as vivid as hearing an actual voice, as opposed to mental imagery or auditory memories. This has lead to propositions that dysregulation of the primary auditory cortex (PAC) is a crucial component of the neural mechanism of AVHs. One possible mechanism by which the PAC could give rise to the experience of hallucinations is aberrant patterns of neuronal activity whereby the PAC is overly sensitive to activation arising from internal processing, while being less responsive to external stimulation. In this paper, we review recent research relevant to the role of the PAC in the generation of AVHs. We present new data from a functional magnetic resonance imaging (fMRI) study, examining the responsivity of the left and right PAC to parametrical modulation of the intensity of auditory verbal stimulation, and corresponding attentional top-down control in non-clinical participants with AVHs, and non-clinical participants with no AVHs. Non-clinical hallucinators showed reduced activation to speech sounds but intact attentional modulation in the right PAC. Additionally, we present data from a group of schizophrenia patients with AVHs, who do not show attentional modulation of left or right PAC. The context-appropriate modulation of the PAC may be a protective factor in non-clinical hallucinations.